{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:50:18Z","timestamp":1793155818303,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We report long-term, end-of-study program safety outcomes from 25 randomized clinical trials (RCTs) in adult patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) [including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)] who received\u2009\u2265\u20091 dose of Ixekizumab (IXE) over 5\u00a0years (PsO) or up to 3\u00a0years (PsA, axSpA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This integrated safety analysis consists of data from patients who received any dose of IXE, across 25 RCTs (17 PsO, 4 PsA, 4 axSpA). Rates of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and selected adverse events (AEs) of interest were analyzed for all pooled studies by years of therapy and overall, through March 2022. Results were reported as exposure-adjusted incidence rates (IRs) per 100 patient-years (PY) overall and at successive year intervals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Six thousand eight hundred ninety two adult patients with PsO, 1401 with PsA, and 932 with axSpA (including AS and nr-axSpA), with a cumulative IXE exposure of 22,371.1 PY were included. The most commonly reported TEAE across indications was nasopharyngitis (IRs per 100 PY: 8.8 (PsO), 9.0 (PsA), 8.4 (axSpA)). SAEs were reported by 969 patients with PsO (IR 5.4), 134 patients with PsA (IR 6.0), and 101 patients with axSpA (IR 4.8). Forty-five deaths were reported (PsO, <jats:italic>n<\/jats:italic>\u2009=\u200936, IR 0.2; PsA, <jats:italic>n<\/jats:italic>\u2009=\u20096, IR 0.3; axSpA, <jats:italic>n<\/jats:italic>\u2009=\u20093, IR 0.1). TEAEs did not increase during IXE exposure: IRs per 100 PY, PsO: 88.9 to 63.2 (year 0\u20131 to 4\u20135), PsA: 87 to 67.3 (year 0\u20131 to 2\u20133), axSpA: 82.1 to 55.4 (year 0\u20131 to\u2009&gt;\u2009\u2009=\u20092). IRs per 100 PY of discontinuation from IXE due to AE were 2.9 (PsO), 5.1 (PsA), and 3.1 (axSpA). IRs per 100 PY of injection site reactions were 5.9 (PsO), 11.6 (PsA) and 7.4 (axSpA); <jats:italic>Candida<\/jats:italic>: 1.9 (PsO), 2.0 (PsA), and 1.2 (axSpA); depression, major adverse cerebro-cardiovascular events and malignancies:\u2009\u2264\u20091.6 across all indications. Adjudicated IRs per 100 PY of inflammatory bowel disease were\u2009\u2264\u20090.8 across indications (0.1 [PsO]; 0.1 [PsA]; 0.8 [axSpA]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this integrated safety analysis, consisting of over 22,000 PY of exposure, the long-term safety profile of IXE was found to be consistent with previous, earlier reports, with no new safety signals identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>NCT registration numbers for RCTs included in this integrated analysis can be found in Additional File 1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-023-03257-7","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:02:37Z","timestamp":1707717757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Long-term safety of Ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials"],"prefix":"10.1186","volume":"26","author":[{"given":"Atul","family":"Deodhar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Feely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadezhda","family":"Eberhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danting","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsie","family":"Grace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Holzkaemper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"8","key":"3257_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41584-019-0256-0","volume":"15","author":"LD Ferguson","year":"2019","unstructured":"Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. Nat Rev Rheumatol. 2019;15(8):461\u201374.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"3257_CR2","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acr.23910","volume":"72","author":"C Fernandez-Carballido","year":"2020","unstructured":"Fernandez-Carballido C, Martin-Martinez MA, Garcia-Gomez C, Castaneda S, Gonzalez-Juanatey C, Sanchez-Alonso F, et al. Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: results from a cross-sectional study. Arthritis Care Res (Hoboken). 2020;72(6):822\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"3257_CR3","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/acr.23567","volume":"70","author":"K Lauper","year":"2018","unstructured":"Lauper K, Courvoisier DS, Chevallier P, Finckh A, Gabay C. Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res (Hoboken). 2018;70(12):1756\u201363.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1\u20132","key":"3257_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s12026-012-8276-8","volume":"52","author":"A Krstic","year":"2012","unstructured":"Krstic A, Mojsilovic S, Jovcic G, Bugarski D. The potential of interleukin-17 to mediate hematopoietic response. Immunol Res. 2012;52(1\u20132):34\u201341.","journal-title":"Immunol Res"},{"issue":"3","key":"3257_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"5","key":"3257_CR6","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/art.33507","volume":"64","author":"TJ Kenna","year":"2012","unstructured":"Kenna TJ, Davidson SI, Duan R, Bradbury LA, McFarlane J, Smith M, et al. Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis. Arthritis Rheum. 2012;64(5):1420\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3257_CR7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/art.24568","volume":"60","author":"H Shen","year":"2009","unstructured":"Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 2009;60(6):1647\u201356.","journal-title":"Arthritis Rheum"},{"key":"3257_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","volume":"9","author":"L Liu","year":"2016","unstructured":"Liu L, Lu J, Allan BW, Tang Y, Tetreault J, Chow CK, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39\u201350.","journal-title":"J Inflamm Res"},{"issue":"1","key":"3257_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14712598.2018.1410133","volume":"18","author":"E Toussirot","year":"2018","unstructured":"Toussirot E. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2018;18(1):101\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"3257_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/bjd.19147","volume":"183","author":"AS Paller","year":"2020","unstructured":"Paller AS, Seyger MMB, Alejandro Magari\u00f1os G, Bagel J, Pinter A, Cather J, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231\u201341.","journal-title":"Br J Dermatol"},{"key":"3257_CR11","unstructured":"Prescribing Information\u2014Taltz. http:\/\/uspl.lilly.com\/taltz\/taltz.html#pi. Accessed 25 September 2023."},{"issue":"12","key":"3257_CR12","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.1093\/rheumatology\/keaa189","volume":"59","author":"MC Genovese","year":"2020","unstructured":"Genovese MC, Mysler E, Tomita T, Papp KA, Salvarani C, Schwartzman S, et al. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. Rheumatology (Oxford). 2020;59(12):3834\u201344.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3257_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","volume":"22","author":"B Combe","year":"2020","unstructured":"Combe B, Rahman P, Kameda H, Canete JD, Gallo G, Agada N, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3257_CR14","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s13555-022-00743-9","volume":"12","author":"CEM Griffiths","year":"2022","unstructured":"Griffiths CEM, Gooderham M, Colombel JF, Terui T, Accioly AP, Gallo G, et al. Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure. Dermatol Ther (Heidelb). 2022;12(6):1431\u201346.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"3257_CR15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79\u201387.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3257_CR16","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2016.09.026","volume":"76","author":"B Strober","year":"2017","unstructured":"Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, et al. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. J Am Acad Dermatol. 2017;76(3):432\u201340 e17.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"3257_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13555-019-00340-3","volume":"10","author":"A Armstrong","year":"2020","unstructured":"Armstrong A, Paul C, Puig L, Boehncke WH, Freeman M, Torii H, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther (Heidelb). 2020;10(1):133\u201350.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"3257_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.15242","volume":"33","author":"RG Langley","year":"2019","unstructured":"Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):333\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9993","key":"3257_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","volume":"386","author":"CEM Griffiths","year":"2015","unstructured":"Griffiths CEM, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541\u201351.","journal-title":"Lancet"},{"issue":"10086","key":"3257_CR20","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","volume":"389","author":"P Nash","year":"2017","unstructured":"Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet (London, England). 2017;389(10086):2317\u201327.","journal-title":"Lancet (London, England)"},{"issue":"9","key":"3257_CR21","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1002\/art.41716","volume":"73","author":"LC Coates","year":"2021","unstructured":"Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, et al. Withdrawing ixekizumab in patients with psoriatic arthritis who achieved minimal disease activity: results from a randomized, double-blind withdrawal study. Arthr Rheumatol (Hoboken, NJ). 2021;73(9):1663\u201372.","journal-title":"Arthr Rheumatol (Hoboken, NJ)"},{"issue":"4","key":"3257_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","volume":"7","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Sebba A, Ruderman EM, Schulze-Koops H, Sapin C, Gellett AM, et al. Efficacy and safety of ixekizumab with or without methotrexate in biologic-na\u00efve patients with psoriatic arthritis: 52-week results from SPIRIT-H2H study. Rheumatol Ther. 2020;7(4):1021\u201335.","journal-title":"Rheumatol Ther"},{"issue":"10163","key":"3257_CR23","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet (London, England). 2018;392(10163):2441\u201351.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"3257_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, et al. Efficacy and Safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors. Arthr Rheumatol (Hoboken, NJ). 2019;71(4):599\u2013611.","journal-title":"Arthr Rheumatol (Hoboken, NJ)"},{"issue":"10217","key":"3257_CR25","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, Ostergaard M, et al. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet (London, England). 2020;395(10217):53\u201364.","journal-title":"Lancet (London, England)"},{"issue":"8","key":"3257_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","volume":"80","author":"RB Landew\u00e9","year":"2021","unstructured":"Landew\u00e9 RB, Gensler LS, Poddubnyy D, Rahman P, Hojnik M, Li X, et al. Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). Ann Rheum Dis. 2021;80(8):1022\u201330.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3257_CR27","doi-asserted-by":"publisher","first-page":"e002165","DOI":"10.1136\/rmdopen-2021-002165","volume":"8","author":"J Braun","year":"2022","unstructured":"Braun J, Kiltz U, Deodhar A, Tomita T, Dougados M, Bolce R, et al. Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST. RMD Open. 2022;8(2):e002165.","journal-title":"RMD Open"},{"issue":"6","key":"3257_CR28","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","volume":"39","author":"S Chabra","year":"2022","unstructured":"Chabra S, Gill BJ, Gallo G, Zhu D, Pitou C, Payne CD, et al. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. Adv Ther. 2022;39(6):2862\u201372.","journal-title":"Adv Ther"},{"issue":"2","key":"3257_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808","volume":"34","author":"B Lockshin","year":"2021","unstructured":"Lockshin B, Cronin A, Harrison RW, McLean RR, Anatale-Tardiff L, Burge R, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the corrona psoriasis registry. Dermatol Ther. 2021;34(2): e14808.","journal-title":"Dermatol Ther"},{"key":"3257_CR30","unstructured":"16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases (jaad.org). https:\/\/www.jaad.org\/action\/showPdf?pii=S0190-9622%2820%2931859-4."},{"issue":"3","key":"3257_CR31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/acr.23738","volume":"71","author":"P Mease","year":"2019","unstructured":"Mease P, Roussou E, Burmester GR, Goupille P, Gottlieb A, Moriarty SR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res (Hoboken). 2019;71(3):367\u201378.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"3257_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","volume":"14","author":"G Murdaca","year":"2015","unstructured":"Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Infection risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf. 2015;14(4):571\u201382.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"3257_CR33","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1517\/14740338.2015.993605","volume":"14","author":"C Selmi","year":"2015","unstructured":"Selmi C, Ceribelli A, Naguwa SM, Cantarini L, Shoenfeld Y. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf. 2015;14(3):389\u201399.","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"3257_CR34","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2011.145","volume":"7","author":"RS Woodrick","year":"2011","unstructured":"Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(11):639\u201352.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"3257_CR35","first-page":"545","volume":"156","author":"C Rodr\u00edguez-Cerdeira","year":"2021","unstructured":"Rodr\u00edguez-Cerdeira C, Gonz\u00e1lez-Cesp\u00f3n JL, Mart\u00ednez-Herrera E, Carnero-Gregorio M, L\u00f3pez-Barcenas A, Sergeev A, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Ital J Dermatol Venerol. 2021;156(5):545\u201357.","journal-title":"Ital J Dermatol Venerol"},{"key":"3257_CR36","doi-asserted-by":"publisher","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","volume":"102","author":"AB Gottlieb","year":"2022","unstructured":"Gottlieb AB, Deodhar A, McInnes IB, Baraliakos X, Reich K, Schreiber S, et al. Long-term safety of Secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data. Acta Derm Venereol. 2022;102:adv00698.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"3257_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12325-019-01145-8","volume":"37","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Gordon KB, Rosenbaum JT, Arikan D, Lau WL, Li P, et al. Long-term safety of Adalimumab in 29,967 adult patients from global clinical trials across multiple indications: an updated analysis. Adv Ther. 2020;37(1):364\u201380.","journal-title":"Adv Ther"},{"issue":"9","key":"3257_CR38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961\u20139.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"3257_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","volume":"3","author":"CT Ritchlin","year":"2019","unstructured":"Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, et al. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatol. 2019;3(1):52.","journal-title":"BMC Rheumatol"},{"issue":"1","key":"3257_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/rheumatology\/keu255","volume":"54","author":"D Wallis","year":"2014","unstructured":"Wallis D, Thavaneswaran A, Haroon N, Ayearst R, Inman RD. Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. Rheumatology. 2014;54(1):152\u20136.","journal-title":"Rheumatology"},{"key":"3257_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100266","volume":"13","author":"L Davidson","year":"2022","unstructured":"Davidson L, van den Reek J, Bruno M, van Hunsel F, Herings RMC, Matzaraki V, et al. Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources. Lancet Reg Health Eur. 2022;13: 100266.","journal-title":"Lancet Reg Health Eur"},{"issue":"2","key":"3257_CR42","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/myc.13399","volume":"65","author":"K Elsner","year":"2022","unstructured":"Elsner K, Holstein J, Hilke FJ, Blumenstock G, Walker B, Schmidt S, et al. Prevalence of Candida species in psoriasis. Mycoses. 2022;65(2):247\u201354.","journal-title":"Mycoses"},{"issue":"12","key":"3257_CR43","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1111\/ijd.12562","volume":"53","author":"M Taheri Sarvtin","year":"2014","unstructured":"Taheri Sarvtin M, Shokohi T, Hajheydari Z, Yazdani J, Hedayati MT. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol. 2014;53(12):e555\u201360.","journal-title":"Int J Dermatol"},{"issue":"4","key":"3257_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","volume":"375","author":"KB Gordon","year":"2016","unstructured":"Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345\u201356.","journal-title":"N Engl J Med"},{"issue":"4","key":"3257_CR45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.36849\/JDD.7344","volume":"22","author":"M Lebwohl","year":"2023","unstructured":"Lebwohl M, Koo J, Leonardi C, Armstrong A, Rawnsley N, Goehring E, et al. Brodalumab: 4-year US pharmacovigilance report. J Drugs Dermatol. 2023;22(4):419\u201322.","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"3257_CR46","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1136\/annrheumdis-2012-202143","volume":"72","author":"WQ Li","year":"2013","unstructured":"Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic arthritis and increased risk of incident Crohn\u2019s disease in US women. Ann Rheum Dis. 2013;72(7):1200\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3257_CR47","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2009.02.015","volume":"61","author":"M Makredes","year":"2009","unstructured":"Makredes M, Robinson D Jr, Bala M, Kimball AB. The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis. J Am Acad Dermatol. 2009;61(3):405\u201310.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3257_CR48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel JF, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3257_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjd.14528","volume":"175","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Mallbris L, Warren RB, Bachelez H, Gislason GH, Hansen PR, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016;175(3):487\u201392.","journal-title":"Br J Dermatol"},{"key":"3257_CR50","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/annrheumdis-2017-212328","volume":"77","author":"R Charlton","year":"2018","unstructured":"Charlton R, Green A, Shaddick G, et al. Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study. Ann Rheum Dis. 2018;77:277\u201380.","journal-title":"Ann Rheum Dis."},{"key":"3257_CR51","unstructured":"Scosyrev E, Primatesta P. Incidence of Crohn\u2019s disease and ulcerative colitis in adult patients with psoriasis vs. the general adult population. J Eur Acad Dermatol Venereol. 2016;30(Suppl 6):3\u2013105. Abstracts of the 5th Congress of the Psoriasis International Network, 7\u20139 July 2016, Paris."},{"issue":"7","key":"3257_CR52","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s10067-018-4086-2","volume":"37","author":"JA Walsh","year":"2018","unstructured":"Walsh JA, Song X, Kim G, Park Y. Evaluation of the comorbidity burden in patients with ankylosing spondylitis using a large US administrative claims data set. Clin Rheumatol. 2018;37(7):1869\u201378.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"3257_CR53","first-page":"367","volume":"9","author":"AN Ananthakrishnan","year":"2013","unstructured":"Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2013;9(6):367\u201374.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"3257_CR54","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrgastro.2017.136","volume":"15","author":"AN Ananthakrishnan","year":"2018","unstructured":"Ananthakrishnan AN, Bernstein CN, Iliopoulos D, Macpherson A, Neurath MF, Ali RAR, et al. Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2018;15(1):39\u201349.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3257_CR55","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/gast.1996.v110.pm8566589","volume":"110","author":"J Cosnes","year":"1996","unstructured":"Cosnes J, Carbonnel F, Beaugerie L, Le Quintrec Y, Gendre JP. Effects of cigarette smoking on the long-term course of Crohn\u2019s disease. Gastroenterology. 1996;110(2):424\u201331.","journal-title":"Gastroenterology"},{"issue":"8","key":"3257_CR56","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/ecco-jcc\/jjv084","volume":"9","author":"SS Poon","year":"2015","unstructured":"Poon SS, Asher R, Jackson R, Kneebone A, Collins P, Probert C, et al. Body mass index and smoking affect Thioguanine nucleotide levels in inflammatory bowel disease. J Crohns Colitis. 2015;9(8):640\u20136.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"3257_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","volume":"14","author":"S Singh","year":"2017","unstructured":"Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110\u201321.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"3257_CR58","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4065\/81.11.1462","volume":"81","author":"SS Mahid","year":"2006","unstructured":"Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462\u201371.","journal-title":"Mayo Clin Proc"},{"key":"3257_CR59","unstructured":"Centers for Disease Control and Prevention. Defining Adult Overweight and Obesity. Accessed July 2023. https:\/\/www.cdc.gov\/obesity\/basics\/adult-defining.html."},{"issue":"4","key":"3257_CR60","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57(4):639\u201347.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"3257_CR61","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","volume":"139","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and risk of inflammatory bowel disease in patients with psoriasis-a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316\u201323.","journal-title":"J Invest Dermatol"},{"issue":"5","key":"3257_CR62","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/apt.16210","volume":"53","author":"CH Lo","year":"2021","unstructured":"Lo CH, Khalili H, Lochhead P, Song M, Lopes EW, Burke KE, et al. Immune-mediated diseases and risk of Crohn\u2019s disease or ulcerative colitis: a prospective cohort study. Aliment Pharmacol Ther. 2021;53(5):598\u2013607.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"3257_CR63","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","volume":"12","author":"C Leonardi","year":"2011","unstructured":"Leonardi C, Papp K, Strober B, Reich K, Asahina A, Gu Y, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol. 2011;12(5):321\u201337.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"3257_CR64","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40264-021-01065-z","volume":"44","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Gottlieb AB, Langley RG, Leonardi CL, Papp KA, Pariser DM, et al. Signal detection and methodological limitations in a real-world registry: learnings from the evaluation of long-term safety analyses in PSOLAR. Drug Saf. 2021;44(6):699\u2013709.","journal-title":"Drug Saf"},{"issue":"4","key":"3257_CR65","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jdv.16018","volume":"34","author":"W Rungapiromnan","year":"2020","unstructured":"Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, et al. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol. 2020;34(4):769\u201378.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3257_CR66","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","volume":"74","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3257_CR67","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-017-1315-z","volume":"19","author":"K Bengtsson","year":"2017","unstructured":"Bengtsson K, Forsblad-d\u2019Elia H, Lie E, Klingberg E, Dehlin M, Exarchou S, et al. Are ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated with an increased risk of cardiovascular events? A prospective nationwide population-based cohort study. Arthritis Res Ther. 2017;19(1):102.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"3257_CR68","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Skov L, Joshi AA, Mallbris L, Gislason GH, Wu JJ, et al. The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J Am Acad Dermatol. 2017;77(4):650\u20136.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"3257_CR69","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.3390\/ijms22169063","volume":"22","author":"D Purzycka-Bohdan","year":"2021","unstructured":"Purzycka-Bohdan D, Kisielnicka A, Bohdan M, Szczerkowska-Dobosz A, Sobalska-Kwapis M, Nedoszytko B, et al. Analysis of the potential genetic links between psoriasis and cardiovascular risk factors. Int J Mol Sci. 2021;22(16):9063.","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"3257_CR70","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/annrheumdis-2016-eular.1921","volume":"75","author":"P Mease","year":"2016","unstructured":"Mease P, Gottlieb A, Menter A, Ritchlin C, Kalia S, Kerdel F, et al. THU0450 all-cause mortality and malignancies in psoriasis patients with psoriatic arthritis in the psoriasis longitudinal assessment and registry study. Ann Rheum Dis. 2016;75(Suppl 2):354\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3257_CR71","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.38385","volume":"66","author":"RL Gross","year":"2014","unstructured":"Gross RL, Schwartzman-Morris JS, Krathen M, Reed G, Chang H, Saunders KC, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthr Rheumatol. 2014;66(6):1472\u201381.","journal-title":"Arthr Rheumatol"},{"issue":"4","key":"3257_CR72","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421\u20139.","journal-title":"JAMA Dermatol"},{"key":"3257_CR73","unstructured":"Minimum Latency & Types or Categories of Cancer. https:\/\/www.cdc.gov\/wtc\/pdfs\/policies\/WTCHP-Minimum-Cancer-Latency-PP-01062015-508.pdf."},{"issue":"4","key":"3257_CR74","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.semarthrit.2018.05.009","volume":"48","author":"X Luo","year":"2019","unstructured":"Luo X, Deng C, Fei Y, Zhang W, Li Y, Zhang X, et al. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. Semin Arthritis Rheum. 2019;48(4):626\u201331.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-023-03257-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-023-03257-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T07:03:36Z","timestamp":1707721416000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-023-03257-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3257"],"URL":"https:\/\/doi.org\/10.1186\/s13075-023-03257-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols for all studies included in this analysis were approved by ethics committees or institutional review boards at participating sites. All studies were conducted in accordance with the ethical principles of the Declaration of Helsinki. Eligible patients provided written informed consent before initiating any study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Competing interests: A.D. reports honorarium and participation in advisory boards at AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, UCB and research grants from AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, UCB. A.B. has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, UCB Pharma, and Ventyx. M.L. reports grants or contracts from Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, and UCB, Inc. A.B. additionally reports consulting fees from Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Apogee Therapeutics, Arcutis, Inc., Aristea Therapeutics, AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Celltrion, Corevitas, Dermavant Sciences, Dr. Reddy, EPI, Evommune, Inc., Facilitatation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Helsinn, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, National Society for Cutaneous Medicine, Pfizer, Seanergy, Strata, Trevi, Verrica, and Vial Health Technologies. M.F. is an associate staff member at Mount Sinai Hospital; is a current employee and shareholder of Eli Lilly and Company; has received consulting, travel, or speaker fees from American Academy of Dermatology, Aerolase, Castle Biosciences, CeraVe-L\u2019Ore\u00b4al, DREAM USA, Galderma Aesthetics, Glow Recipe, La Roche-Posay-L\u2019Ore\u00b4al, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical. A.K., N.E., D.Z., E.I., E.G. and T.H. are current employees and shareholders of Eli Lilly and Company. P.R. reports consulting fees and honorarium from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly and Company, Janssen, Novartis, Pfizer and UCB. P.R. additionally reports support for attending meetings and\/or travel from AbbVie, Janssen and UCB and a leadership or fiduciary role at the Canadian Academy of Health Science and Council of Canadian Academies. H.M.O. reports grants from Janssen, Novartis, Pfizer and UCB, consulting fees from Abbvie, Eli Lilly and Company, Hanssen, Moonlake, Novartis, Pfizer and UCB; support for attending meetings and\/or travel from Janssen and Novartis; honorarium from Abbvie, Biogen, Eli Lilly and Company, Janssen, Novartis, Pfizer, Takeda and UCB; leadership or fiduciary role as Chair of the British Society for Spondyloarthritis. K.P. reports consultant, speakers bureau, clinical research grants, honoraria, steering committee membership and advisory board participation and participation as a scientific officer among the following; AbbVie, Acelyrin, Akros, Amgen, Anacor, Aralez Pharma, Arcutis, Avillion, Bausch Health, Boehring Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Celltrion, Coherus, Dermavent, Dermira, Dice Pharma, Dow Pharma, Eli Lilly and Company, Evelo, Forbion, Galderma, Gilead, GSK, Incyte, Janssen, Kyowa Hakka Kirin, Leo, Meiji Seika Pharma, Merck, Mitsubishi Pharma, Novartis, Pfizer, Regeneron, Reistone, Roche, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, UCB, vTv Therapeutics, Xencor. J.F.M. is a consultant and\/or investigator for Amgen, Boehringer Inhelheim, Bristol-Myers Squibb, Abbvie, Dermavant, Eli Lilly, Incyte, Novartis, Janssen, UCB, Sanofi-Regeneron, Sun Pharma, Biogen, Pfizer and Leo Pharma. A.G. received honoraria as an advisory board member and consultant for Amgen, AnaptypsBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Dice Therapeutics, Eli Lilly and Company, Janssen, Novartis, Sanofi, UCB, and Xbiotech and has received research\/educational grants from AnaptypsBio, Moonlake Immunotherapeutics AG, Novartis, Bristol-Myers. Squibb, and UCB Pharma, (all paid to Mount Sinai School of Medicine). S.S. has served as a speaker and consultant with Abbvie, Janssen, Eli Lilly and Company and UCB; additionally, as a speaker with Pfizer and additionally as a consultant with Myriad, Novartis, Regeneron, Sanofi, Stelexis, Jubilant and Teijin and a board member of the National Psoriasis Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}